secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2023-04-21T23:59:59+00:00
Accession:  0001824293-23-000065
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vallon shareholders approve merger with GRI Bio; reverse split set at 1-for-30
------------------------------------------------------------------------------

- 91% of votes cast favored Proposal 1 (issuance of shares & change of control); merger expected to close April 21, 2023.
- Board set reverse split ratio at 1-for-30; post-split shares to trade under ticker 'GRI' starting April 24, 2023.
- Altium Capital to invest ~$15M total; $2.5M already invested, $12.25M due at close.
- Combined company will focus on GRI Bio's NKT cell modulator pipeline for inflammation, fibrosis & autoimmune diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000065/0001824293-23-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000065/val-20230420.htm
  HTML page:      https://secwatch.observer/filing/0001824293-23-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer